Literature DB >> 19409036

Affinity and avidity in antibody-based tumor targeting.

Stephen I Rudnick1, Gregory P Adams.   

Abstract

Many factors contribute to successful tumor targeting by antibodies. Besides properties of the tumor tissue and general antibody pharmacology, a relationship exists between an antibody and its antigen that can shape penetration, catabolism, specificity, and efficacy. The affinity and avidity of the binding interactions play critical roles in these dynamics. In this work, we review the principles that guide models predicting tumor penetration and cellular internalization while providing a critical overview of studies aimed at experimentally determining the specific role of affinity and avidity in these processes. One should gain the perspective that binding affinity can, in part, dictate the localization of antibodies in tumors, leading to high concentrations in the perivascular space or low concentrations diffused throughout the tumor. These patterns can be simply due to the diminution of available dose by binding antigen and are complicated by internalization and degradation stemming from slow rates of dissociation. As opposed to the trend of simply increasing affinity to increase efficacy, novel strategies that increase avidity and broaden specificity have made significant progress in tumor targeting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409036      PMCID: PMC2902227          DOI: 10.1089/cbr.2009.0627

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  47 in total

Review 1.  Antibody engineering principles and applications.

Authors:  LiNa Loo; Matthew K Robinson; Gregory P Adams
Journal:  Cancer J       Date:  2008 May-Jun       Impact factor: 3.360

2.  PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting.

Authors:  Susanne Kubetzko; Ela Balic; Robert Waibel; Uwe Zangemeister-Wittke; Andreas Plückthun
Journal:  J Biol Chem       Date:  2006-09-08       Impact factor: 5.157

Review 3.  Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors.

Authors:  Robert A Beckman; Louis M Weiner; Hugh M Davis
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

4.  Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.

Authors:  Jennifer H E Baker; Kirstin E Lindquist; Lynsey A Huxham; Alastair H Kyle; Jonathan T Sy; Andrew I Minchinton
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

6.  Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.

Authors:  Sergey M Deyev; Ekaterina N Lebedenko
Journal:  Bioessays       Date:  2008-09       Impact factor: 4.345

Review 7.  Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Authors:  Greg M Thurber; Michael M Schmidt; K Dane Wittrup
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

8.  Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.

Authors:  Yong Tang; Jianlong Lou; R Katherine Alpaugh; Matthew K Robinson; James D Marks; Louis M Weiner
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

9.  Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.

Authors:  Margaret E Ackerman; David Pawlowski; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

10.  Theoretic criteria for antibody penetration into solid tumors and micrometastases.

Authors:  Greg M Thurber; Stefan C Zajic; K Dane Wittrup
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more
  74 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 2.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

3.  Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.

Authors:  Andreas Lehmann; Josephine H F Wixted; Maxim V Shapovalov; Heinrich Roder; Roland L Dunbrack; Matthew K Robinson
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

Review 4.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 5.  Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Authors:  Yingzhi Chen; Meng Zhang; Kyoung Ah Min; Huiyuan Wang; Meong Cheol Shin; Feng Li; Victor C Yang; Yongzhuo Huang
Journal:  Curr Drug Targets       Date:  2018-02-19       Impact factor: 3.465

6.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

Review 7.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

8.  FEZ1 Is Recruited to a Conserved Cofactor Site on Capsid to Promote HIV-1 Trafficking.

Authors:  Pei-Tzu Huang; Brady James Summers; Chaoyi Xu; Juan R Perilla; Viacheslav Malikov; Mojgan H Naghavi; Yong Xiong
Journal:  Cell Rep       Date:  2019-08-14       Impact factor: 9.423

9.  Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.

Authors:  Shigehiro Asano; Julia Gavrilyuk; Dennis R Burton; Carlos F Barbas
Journal:  ACS Med Chem Lett       Date:  2014-02-13       Impact factor: 4.345

Review 10.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.